.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
Transpara Breast AI is the technology of choice for first large-scale RCT in the United States to evaluate the role of AI in breast cancer screening.
.png)
ScreenPoint Medical expands in Spain with SACYL - EUSOBI 2025
ScreenPoint Medical partners with SACYL to bring AI for breast cancer detection to Castilla y León, enhancing screening accuracy and efficiency in Spain.
.png)
New study assesses cost-effectiveness of Transpara as part of national screening protocol
Is it possible to reduce the total cost for the healthcare system and simultaneously boost quality-adjusted life years across a population?
.png)
Transpara AI boosts breast cancer detection without increasing reading time, study finds
Radiologists can improve breast cancer detection accuracy with Transpara, according to new research.
.png)
Ikonopedia Enhances Breast Cancer Detection with Integrated AI Technology from ScreenPoint Medical
New Transpara integration provides radiologists with automated insights for more accurate and productive patient diagnoses and care.
.png)
Podcast: ScreenPoint Co-Founder Talks Future of Breast Cancer Screening
Nico Karssemeijer, Chief Science Officer and Co-Founder of ScreenPoint Medical, joins Impact AI podcast to discuss how his team is revolutionizing breast cancer screening through cutting-edge AI.